Platelets and megakaryocytes in cancer.

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Platelets are crucial for hemostasis but also implicated in cancer metastasis and inflammation.
• Megakaryocytes, platelet precursors, are primarily found in bone marrow.
• Elevated platelet counts and platelet-to-lymphocyte ratio are investigated as cancer biomarkers.

Purpose of the Study:

• To review the multifaceted roles of platelets and megakaryocytes in cancer progression and metastasis.
• To discuss potential cancer-suppressing functions of platelets, particularly in regulating vascular integrity.
• To examine the involvement of platelets in cancer immune checkpoint therapy and drug delivery systems.

Main Methods:

• Review of experimental models, primarily murine, detailing platelet-mediated metastasis.
• Exploration of emerging research on megakaryocyte roles in solid cancers, myeloma, and lymphoma.
• Analysis of recent advancements in cancer immune checkpoint therapy and platelet-based drug delivery.

Main Results:

• Platelets and megakaryocytes contribute to cancer progression and metastasis through various mechanisms.
• Platelets may also exert cancer-suppressing effects by regulating intratumoral vascular integrity.
• Platelets show potential in targeted drug delivery systems and in modulating cancer immune responses.

Conclusions:

• Platelets and megakaryocytes have complex, often opposing, roles in cancer biology.
• Further research into platelet functions could yield novel biomarkers and therapeutic strategies for cancer.
• The interplay between platelets, megakaryocytes, and cancer warrants continued investigation for clinical applications.